Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 23
Filtrar
1.
Plant Foods Hum Nutr ; 78(4): 654-661, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-37796415

RESUMEN

Parkinson's disease (PD) and other age-related neurodegenerative ailments have a strong link to oxidative stress. Bioflavonoid naringenin has antioxidant properties. The effects of pre- and post-naringenin supplementation on a rotenone-induced PD model were examined in this work. Naringenin (50 mg/kg, p.o.) was administered to rats for two weeks before the administration of rotenone in the pre-treatment phase. In contrast, rotenone (1.5 mg/kg, s.c.) was administered for eight days before naringenin (50 mg/kg, p.o.) was supplemented for two weeks in the post-treatment phase. During behavioral investigation, the motor and non-motor signs of PD were observed. Additionally, estimation of neurochemical and biochemical parameters was also carried out. Compared to controls, rotenone treatment substantially increased oxidative stress, altered neurotransmitters, and caused motor and non-motor impairments. Rotenone-induced motor and non-motor impairments were considerably reduced by naringenin supplementation. The supplementation also increased antioxidant enzyme activities and restored the changes in neurotransmitter levels. The findings of this work strongly imply that daily consumption of flavonoids such as naringenin may have a therapeutic potential to combat PD.


Asunto(s)
Fármacos Neuroprotectores , Trastornos Parkinsonianos , Ratas , Animales , Rotenona/toxicidad , Antioxidantes/farmacología , Alimentos Funcionales , Modelos Animales de Enfermedad , Trastornos Parkinsonianos/inducido químicamente , Trastornos Parkinsonianos/tratamiento farmacológico , Estrés Oxidativo , Fármacos Neuroprotectores/efectos adversos
2.
Neurochem Res ; 46(12): 3273-3285, 2021 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-34409523

RESUMEN

Depressive state adversely affects the memory functions, especially in the geriatric population. The initial stage of memory deficits associated with depression is particularly called as pseudodementia. It is the starting point of memory disturbance before dementia. The purpose of this research was to study depression and its consequent pseudodementia. For this purpose 24 male albino Wistar rats were divided into four groups. Depression was induced by 14 days of chronic restraint stress (CRS) daily for 4 h. After developing a depression model, pattern separation test was conducted to monitor pseudodementia in rats. Morris water maze test (MWM) was also performed to observe spatial memory. It was observed that model animals displayed impaired pattern separation and spatial memory. Treatment was started after the development of pseudodementia in rats. Curcumin at a dose of 200 mg/kg was given to model rats for one week along with the stress procedure. Following the treatment with curcumin, rats were again subjected to the aforementioned behavioral tests before decapitation. Corticosterone levels, brain derived neurotrophic factor (BDNF) and neurochemical analysis were conducted. Model rats showed depressogenic behavior and impaired memory performance. In addition to this, high corticosterone levels and decreased hippocampal BDNF, 5-HT, dopamine (DA), and acetylcholine (ACh) levels were also observed in depressed animals. These behavioral biochemical and neurochemical changes were effectively restored following treatment with curcumin. Hence, it is suggested from this study that pseudodementia can be reversed unlike true dementia by controlling the factors such as depression which induce memory impairment.


Asunto(s)
Factor Neurotrófico Derivado del Encéfalo/metabolismo , Curcumina/farmacología , Depresión/tratamiento farmacológico , Dopamina/metabolismo , Trastornos Fingidos/prevención & control , Hipocampo/efectos de los fármacos , Neurotransmisores/metabolismo , Animales , Antiinflamatorios no Esteroideos/farmacología , Factor Neurotrófico Derivado del Encéfalo/genética , Corticosterona/metabolismo , Depresión/metabolismo , Depresión/patología , Trastornos Fingidos/etiología , Trastornos Fingidos/metabolismo , Trastornos Fingidos/patología , Hipocampo/metabolismo , Hipocampo/patología , Masculino , Ratas , Ratas Wistar , Estrés Fisiológico
3.
Neurochem Res ; 45(11): 2762-2774, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-32918662

RESUMEN

Noise has always been an important environmental factor that induces health problems in the general population. Due to ever increasing noise pollution, humans are facing multiple auditory and non-auditory problems including neuropsychiatric disorders. In modern day life it is impossible to avoid noise due to the rapid industrialization of society. Continuous exposure to noise stress creates a disturbance in brain function which may lead to memory disorder. Therefore, it is necessary to find preventive measures to reduce the deleterious effects of noise exposure. Supplementation of taurine, a semi essential amino acid, is reported to alleviate psychiatric disorders. In this study noise-exposed (100 db; 3 h daily for 15 days) rats were supplemented with taurine at a dose of 100 mg/kg for 15 days. Spatial and recognition memory was assessed using the Morris water maze and novel object recognition task, respectively. Results of this study showed a reversal of noise-induced memory impairment in rats. The derangements of catecholaminergic and serotonergic levels in the hippocampus and altered brain antioxidant enzyme activity due to noise exposure were also restored by taurine administration. This study highlights the importance of taurine supplementation to mitigate noise-induced impaired memory via normalizing the neurochemical functions and reducing oxidative stress in rat brain.


Asunto(s)
Trastornos de la Memoria/tratamiento farmacológico , Fármacos Neuroprotectores/uso terapéutico , Ruido/efectos adversos , Estrés Oxidativo/efectos de los fármacos , Memoria Espacial/efectos de los fármacos , Taurina/farmacología , Animales , Masculino , Prueba del Laberinto Acuático de Morris/efectos de los fármacos , Prueba de Campo Abierto/efectos de los fármacos , Ratas Wistar , Reconocimiento en Psicología/efectos de los fármacos
4.
Pak J Pharm Sci ; 32(1(Supplementary)): 277-283, 2019 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-30829204

RESUMEN

Magnesium (Mg) is an essential biomineral that acts as an intracellular cofactor for more than 300 enzymes. It is an important modulator of the N-methyl-D-aspartate (NMDA) receptor which is involved in memory function and depression. The purpose of this study was to compare the dose dependent effect of oral supplementation of Magnesium chloride (MgCl2), Magnesium sulphate (MgSO4) and Magnesium-L-threonate (MgT) on memory and depression-related behaviors in rats. Rats were orally administered with different doses (50 mg/kg, 100 mg/kg and 150 mg/kg) of each Mg salt. Following 28 days of oral supplementation, animals were subjected to behavioral tests. After completion of behavioral test, rats were decapitated. Brain and plasma samples were used for neurochemical and biochemical analysis. Assessment of behaviors in elevated plus maze (EPM) test and forced swim test (FST) showed that MgT more significantly improved memory of rats and decreased depression-like symptoms in healthy rats as compared to controls. Biochemical analysis indicated significant increase in plasma Mg levels dose dependently following MgT administration. This increase might be related to observe enhanced cholinergic functions and decline in oxidative stress in rats in the present study. This comparative study highlights that MgT (100mg/kg) is the most appropriate Mg salt and dose for oral treatment that strengthens cholinergic system and improves brain related functions through attenuation of oxidative burden in adult healthy rats.


Asunto(s)
Encéfalo/efectos de los fármacos , Butiratos/farmacología , Cloruro de Magnesio/farmacología , Sulfato de Magnesio/farmacología , Memoria/efectos de los fármacos , Acetilcolina/metabolismo , Animales , Conducta Animal/efectos de los fármacos , Encéfalo/metabolismo , Butiratos/administración & dosificación , Depresión/tratamiento farmacológico , Relación Dosis-Respuesta a Droga , Magnesio/sangre , Cloruro de Magnesio/administración & dosificación , Sulfato de Magnesio/administración & dosificación , Masculino , Ratas Wistar
5.
Pak J Pharm Sci ; 32(4(Supplementary)): 1893-1900, 2019 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-31680089

RESUMEN

Unpredictable chronic mild stress (UCMS) model is the most established method to study neurobiological mechanisms of depression. This work was intended to explore the efficacy of curcumin to revert the UCMS-induced oxidative burden and associated depression as well as potential of curcumin as an acetyl cholinesterase (AchE) inhibitor. Animals were initially grouped into control and curcumin (200mg/kg, p.o) and further subdivided into unstressed and stressed groups. Depression and anxiety were evaluated by forced swim test (FST) and light/dark transition (LDT) while memory function was assessed by passive avoidance test (PAT). Effect of curcumin on oxidative stress following UCMS was determined by measuring peroxidation of lipid (LPO) and antioxidant enzyme activities. AchE activity was also determined. Findings showed that curcumin supplementation significantly attenuated the UCMS-induced depression and anxiety like symptoms, decreased the load of UCMS propagated oxidative stress by improving antioxidant enzymes activities. Curcumin also improved the memory function and exhibited inhibitory effect on AchE activity. In conclusion it can be suggested that supplementation of curcumin in daily life can help in combating the stress-induced depression and ever increasing load of oxidative stress. Study also highlights the anti-acetylcholinesterase potential of curcumin which may be responsible for improved memory function following UCMS.


Asunto(s)
Acetilcolinesterasa/metabolismo , Inhibidores de la Colinesterasa/farmacología , Curcumina/farmacología , Depresión/tratamiento farmacológico , Trastornos de la Memoria/tratamiento farmacológico , Estrés Oxidativo/efectos de los fármacos , Estrés Psicológico/tratamiento farmacológico , Animales , Antioxidantes/farmacología , Ansiedad/tratamiento farmacológico , Ansiedad/metabolismo , Depresión/metabolismo , Peroxidación de Lípido/efectos de los fármacos , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Memoria/efectos de los fármacos , Trastornos de la Memoria/metabolismo , Ratones , Ratas Wistar , Estrés Psicológico/metabolismo
6.
Pak J Pharm Sci ; 31(5(Supplementary)): 2179-2184, 2018 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-30393230

RESUMEN

Major depressive disorder (MDD) is the leading cause of memory impairment in general population. The serotonin hypothesis provides a target model for the treatment of depression and depression-associated memory loss. 5-HT-1B receptor is suggested as a potential candidate in the pathophysiology of depressive illness. Dysfunction of 5-HT-1B receptors has been observed previously in depressive patients. Zolmitriptan, 5-HT-1B agonist is clinically recommended for the treatment of migraine. However, in present study this drug was tested as a potential treatment for depression and associated memory loss by altering the serotonergic function at receptor level. Rats (n=24) were equally divided into unstressed and stressed groups. Depression was induced by 19 days of restraint stress for 4 h which was followed by forced swim test and pattern separation test to assess depressive symptoms and memory impairment, respectively. The initial sign of depression-associated memory loss involves impaired pattern separation which is regarded as pseudodementia. In this study stressed rats showed depression- and pseudodementia-like symptoms. After the induction of depression, rats were treated with zolmitriptan at a dose of 0.3 mg/kg which resulted in a significant attenuation of depression and depression-associated memory impairment. Results are discussed with reference to the modulation of function of 5-HT-1B receptor following the administration of exogenous agonist.


Asunto(s)
Depresión/tratamiento farmacológico , Depresión/psicología , Trastornos Fingidos/tratamiento farmacológico , Trastornos Fingidos/psicología , Oxazolidinonas/uso terapéutico , Agonistas del Receptor de Serotonina 5-HT1/uso terapéutico , Triptaminas/uso terapéutico , Animales , Depresión/complicaciones , Trastornos Fingidos/etiología , Masculino , Ratas , Ratas Wistar
7.
Pak J Pharm Sci ; 31(3(Supplementary)): 1075-1079, 2018 May.
Artículo en Inglés | MEDLINE | ID: mdl-29731446

RESUMEN

Post-traumatic stress disorder (PTSD) is a condition which is triggered shortly after experiencing traumatic events. PTSD is complicated by the fact that people with PTSD often develop additional disorders such as phobias, addiction, depression, panic disorder and obsessive-compulsive disorder. Beta-adrenergic and cholinergic system both are involved in memory formation as well as in emotional response associated with memory. It is reported that the administration of beta-adrenergic and cholinergic antagonist results in the impairment in memory formation. Here, we examined the potential of beta-adrenergic antagonist propranolol and muscarinic cholinergic antagonist atropine for impairing the recently formed fear memory associated with PTSD. Reconsolidation is the memory process during which labile memory converts into permanent memory. In this study it is hypothesized that if recently formed fear memory is disturbed during reconsolidation phase by pharmacological intervention then it could be possible to impair well-consolidated fear memory. Atropine and propranolol were injected in separate set of rats (n=6) just after the reactivation of fear memory. Short term memory and long term memory were monitored after 2 h and 24 h of reactivation respectively. Results of current study demonstrated that only atropine showed significant impairment of reconsolidation of newly formed fear memory whereas propranolol did not show fear memory disrupting effects. The results emphasize the significance of pharmacological intervention to impair reconsolidation of newly formed fear memory.


Asunto(s)
Atropina/farmacología , Miedo/efectos de los fármacos , Consolidación de la Memoria/efectos de los fármacos , Propranolol/farmacología , Animales , Condicionamiento Clásico/efectos de los fármacos , Masculino , Ratas
8.
Pak J Pharm Sci ; 30(3(Suppl.)): 943-948, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-28655689

RESUMEN

Rotenone (organic pesticide and inhibitor of mitochondrial complex I) is used to generate an experimental model of Parkinson's disease (PD). In the present study, we investigated rotenone-induced locomotor deficits, gait dynamics and muscular weakness in rats. The study also determined dopamine (DA) and dihydroxyphenylacetic acid (DOPAC) levels following rotenone administration. In the study, adult male rats were administered subcutaneously (s.c.) with rotenone (1.5 mg/kg/day) for 8 days. Motor activities were monitored by the Kondziela's inverted screen test, beam walking test and footprint test. Animals were decapitated after behavioral analysis and brains were dissected out for neurochemical estimation. Results showed that the levels of DA and DOPAC were significantly decreased, which further supported by significant impaired motor coordination in rotenone treated rats. In conclusion, the behavioral and neurochemical findings of our study further strengthen the previous report and emphasizes on short term administration of rotenone producing PD-like symptoms in rats.


Asunto(s)
Modelos Animales de Enfermedad , Marcha/fisiología , Actividad Motora/fisiología , Enfermedad de Parkinson Secundaria/fisiopatología , Rotenona , Ácido 3,4-Dihidroxifenilacético/análisis , Animales , Conducta Animal/fisiología , Química Encefálica/efectos de los fármacos , Dopamina/análisis , Masculino , Debilidad Muscular/etiología , Enfermedad de Parkinson Secundaria/inducido químicamente , Enfermedad de Parkinson Secundaria/complicaciones , Ratas , Ratas Wistar
9.
Pak J Pharm Sci ; 30(2(Suppl.)): 647-653, 2017 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-28650335

RESUMEN

Alzheimer's disease (AD) is an age-related neurodegenerative disorder associated with neurochemical and neurobehavioural alterations. Aluminium (Al) is considered as a contributing factor in the etiology of several neurodegenerative disorders like AD. D-galactose (D-gal) is a physiological nutrient but over supply induces some neurochemical and biochemical changes that exacerbate natural aging process. In this study, we aimed to develop AD animal model by co-administration of Al and D-gal in rats. Male albino Wistar rats were intraperitoneally injected with AlCl3 and D-gal at a dose of 150mg/kg and 300mg/kg respectively for one week. After one week rats were subjected to behavioural analysis. After behavioural analysis rats were decapitated to remove their brain. Biochemical and neurochemical analysis were conducted in whole brain. AlCl3+D-gal significantly induced depressive and anxious behaviour in rats. Rats cognitive abilities were also significantly impaired following AlCl3 and D-gal co-administration. AlCl3+D-gal significantly altered antioxidant enzyme activities and biogenic amine levels in whole brain. A marked increase in brain lipid peroxidation and acetylcholinesterase activity was found in test rats. These findings suggest that co-administration of AlCl3 and D-gal for one week could induce AD like symptoms and may be used to develop AD animal model.


Asunto(s)
Cloruro de Aluminio/toxicidad , Enfermedad de Alzheimer/inducido químicamente , Conducta Animal/efectos de los fármacos , Modelos Animales de Enfermedad , Galactosa/toxicidad , Acetilcolinesterasa/metabolismo , Enfermedad de Alzheimer/metabolismo , Animales , Antioxidantes/metabolismo , Aminas Biogénicas/metabolismo , Encéfalo/metabolismo , Peroxidación de Lípido/efectos de los fármacos , Masculino , Ratas
10.
Pak J Pharm Sci ; 30(1 Suppl): 273-279, 2017 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-28625954

RESUMEN

Excessive exposure of cadmium which is regarded as a neurotoxin can stimulate aging process by inducing abnormality in neuronal function. It has been reported that supplementation of almond and walnut attenuate age-related memory loss. Present study was designed to investigate the weekly administration of cadmium for one month on learning and memory function with relation to cholinergic activity. Cadmium was administered at the dose of 50 mg/kg/week. Whereas, almond and walnut was supplemented at the dose of 400 mg/kg/day along with cadmium administration to separate set of rats. At the end of experiment, memory function was assessed by Morris water maze, open field test and novel object recognition test. Results of the present study showed that cadmium administration significantly reduced memory retention. Reduced acetylcholine levels and elevated acetyl cholinesterase activity were also observed in frontal cortex and hippocampus of cadmium treated rats. Malondialdehyde levels were also significantly increased following the administration of cadmium. Daily supplementation of almond and walnut for 28 days significantly attenuated cadmium-induced memory impairment in rats. Results of the present study are discussed in term of cholinergic activity in cadmium-induced memory loss and its attenuation by nuts supplementation in rats.


Asunto(s)
Cadmio/administración & dosificación , Colinérgicos/administración & dosificación , Habituación Psicofisiológica/efectos de los fármacos , Hipocampo/efectos de los fármacos , Trastornos de la Memoria/inducido químicamente , Trastornos de la Memoria/dietoterapia , Memoria/efectos de los fármacos , Acetilcolina/metabolismo , Envejecimiento/efectos de los fármacos , Animales , Suplementos Dietéticos , Juglans , Aprendizaje por Laberinto/efectos de los fármacos , Prunus dulcis , Ratas , Ratas Wistar
11.
Pak J Pharm Sci ; 30(5(Supplementary)): 1957-1963, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-29105628

RESUMEN

Energy drinks enhance physical endurance and cognitive ability. The ingredients present in these drinks are considered as ergogenic and have memory boosting effects. In the present study effects of taurine administration for one week was monitored on physical exercise and memory performance in rats. Animals were divided into two groups namely control and test. Taurine was injected intraperitoneally to the test group at the dose of 100mg/kg. After one week of treatment rats were subjected to physical exercise and memory task. Results of this study revealed that rats injected with taurine for one week exhibited improved muscular strength as well as enhanced memory performance in Morris water maze and elevated plus maze. Biomarker of lipid peroxidation was significantly reduced in brain and plasma of test animals. Taurine administration also resulted in higher levels of corticosterone in this study. The results highlight the significance of taurine ingestion in energy demanding and challenging situations in athletes and young subjects.


Asunto(s)
Conducta Animal/efectos de los fármacos , Memoria/efectos de los fármacos , Músculo Esquelético/efectos de los fármacos , Resistencia Física/efectos de los fármacos , Taurina/administración & dosificación , Animales , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Catalasa/metabolismo , Esquema de Medicación , Hidrocortisona/sangre , Inyecciones Intraperitoneales , Peroxidación de Lípido/efectos de los fármacos , Malondialdehído/metabolismo , Aprendizaje por Laberinto/efectos de los fármacos , Fuerza Muscular/efectos de los fármacos , Músculo Esquelético/fisiología , Ratas Wistar , Factores de Tiempo
12.
Pak J Pharm Sci ; 30(6(Supplementary)): 2423-2427, 2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-29188780

RESUMEN

Schizophrenia (SZ) is categorized as neuropsychiatric disorder with reduced lifespan and significant impairments in social and vocational functioning. One of the best proposed pharmacological animal models is dizocilpine, as it can mimic the full spectrum of schizophrenic disorder including positive and negative symptoms along with cognitive deficits. Dizocilpine is N-methyl-D-aspartate (NMDA) receptor antagonist known to induce hyper-locomotion and stereotyped behavior in rodents. Present study was designed to develop an animal model of SZ via intraperitoneal administration of dizocilpine in rats (100-150g) at a dose of 0.3 mg/kg for eight days. For the evaluation of positive symptoms, hyperlocomotor behavior was monitored. Negative symptoms were assessed by sucrose preference test (SPT) and social interaction test (SIT). Moreover, Cognitive deficits were evaluated by novel object recognition test (NORT). After behavioral assessments animals were decapitated for further evaluation of biochemical and neurochemical estimations. Present findings revealed that dizocilpine injected rats exhibited significant hyperlocomotor behavior, depressive symptoms and cognitive deficits. Results are further strengthened with a marked increase in lipid per oxidation (LPO) in brain and a decline in reduced glutathione (GSH) levels. Biogenic amine levels (Dopamine, DA; 5-hydroxytryptamine, 5-HT) were also significantly increased and decreased respectively. Thus, present findings suggest that dizocilpine can be used as one of the best drug to develop psychosis-like symptoms in rats and to develop an animal model following a short-term study.


Asunto(s)
Conducta Animal , Esquizofrenia/inducido químicamente , Psicología del Esquizofrénico , Animales , Encéfalo/metabolismo , Encéfalo/fisiopatología , Cognición , Modelos Animales de Enfermedad , Maleato de Dizocilpina , Dopamina/metabolismo , Preferencias Alimentarias , Glutatión/metabolismo , Relaciones Interpersonales , Peroxidación de Lípido , Locomoción , Masculino , Estrés Oxidativo , Ratas Wistar , Esquizofrenia/metabolismo , Esquizofrenia/fisiopatología , Serotonina/metabolismo , Conducta Estereotipada , Factores de Tiempo
13.
Heliyon ; 10(1): e23264, 2024 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-38163119

RESUMEN

Rheumatoid arthritis (RA) is an autoimmune disorder with unknown aetiology. Patients suffering from RA face persistent pain due to joint inflammation, and tissue destruction. Behavioural phenotyping is an approach to target the role of different behavioural traits associated with disease progression. The study aimed to assess behavioural patterns associated with decreased muscle strength in the adjuvant-induced rheumatoid arthritis animal model. The study was conducted on male Albino Wister rats (n = 30) [Control, Vehicle, and Disease groups]. After taking ethical approvals RA was induced by complete Freund's adjuvant (CFA) intradermally base of tail. The weight of animals, macroscopic analysis of inflammatory signs, and arthritic scores were measured weekly. Grip strength, ganglia-based movement, cataleptic activity, and motor-coordination-related behaviours were assessed among the groups. Radiographs and spleen index assay were performed followed by data analysis using one-way and two-way ANOVA (Analysis of Variance). A significant decrease in weight and an increase in arthritic scores among the diseased group was observed. Behavioural analyses confirmed that diseased animals had significantly decreased grip strength and increased cataleptic activity with less motor coordination. Radiographic images and spleen index assay confirmed the pattern of RA. Therefore, it can be suggested that the development of the disease animal model is an effective approach to identifying the disease progression and associated behavioural changes. Moreover, this prepared laboratory animal model may be utilised for pathway analyses to understand the key role of immune regulators and genetic insight into molecular pathways associated with acute and chronic phases of RA.

14.
Life Sci ; 277: 119417, 2021 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-33794248

RESUMEN

AIMS: Schizophrenia (SZ) is recognized as a neuropsychiatric disorder in humans with accelerated mortality and profound morbidity followed with impairments in social as well as vocational functioning. Though various antipsychotics are being considered as approved treatment therapy for the psychotic symptoms of SZ but they also exert adverse effects and also lack efficacy in treating full spectrum of the disorder. Spirulina platensis (blue-green algae), a nutritional supplement, constitutes a variety of multi-nutrients and possesses a large number of neuroprotective activities. Therefore, present experimental work was designed to evaluate the neuroprotective effects of spirulina in ameliorating the psychosis-like symptoms in dizocilpine-induced rat model of SZ. MATERIALS AND METHODS: The spirulina was tested as preventive and therapeutic regimen at the dose of 180 mg/kg. After pre- and post-treatment with spirulina, rats were subjected to behavioral assessments followed by biochemical and neurochemical estimations. Biomarkers including APO-E, RTN-4, TNF-α, and IL-6 were also estimated using ELISA. KEY FINDINGS: Present results showed that administration of spirulina not only improved behavioral deficits induced by dizocilpine but it also regulates neurotransmission, oligodendrocyte dysfunction and APO-E over expression. Moreover, it also restores the immune response dysfunction by reducing inflammatory cytokines. SIGNIFICANCE: Thus, from present findings it may be suggested that spirulina aids in ameliorating the psychosis-like symptoms induced by dizocilpine in animal model possibly via regulation of neurotransmission and other biomarkers that are extensively used to uncover the etiopathology of SZ. Hence, blue-green algae can be used as an effective therapy for preventive or therapeutic measures in SZ.


Asunto(s)
Apolipoproteínas E/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Proteínas Nogo/metabolismo , Corteza Prefrontal/efectos de los fármacos , Esquizofrenia/prevención & control , Spirulina/fisiología , Animales , Apolipoproteínas E/genética , Conducta Animal/efectos de los fármacos , Suplementos Dietéticos , Modelos Animales de Enfermedad , Masculino , Proteínas Nogo/genética , Estrés Oxidativo , Corteza Prefrontal/metabolismo , Ratas , Ratas Wistar , Esquizofrenia/genética , Esquizofrenia/metabolismo , Esquizofrenia/patología
15.
PLoS One ; 16(11): e0258928, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34767546

RESUMEN

The rotenone-induced animal model of Parkinson's disease (PD) has been used to investigate the pathogenesis of PD. Oxidative stress is one of the main contributors of neurodegeneration in PD. Flavonoids have the potential to modulate neuronal function and combat various neurodegenerative diseases. The pre- and post-supplementation of quercetin (50 mg/kg, p.o) was done in rats injected with rotenone (1.5 mg/kg, s.c). After the treatment, behavioral activities were monitored for motor activity, depression-like behavior, and cognitive changes. Rats were decapitated after behavioral analysis and the brain samples were dissected out for neurochemical and biochemical estimation. Results showed that supplementation of quercetin significantly (p<0.01) restored rotenone-induced motor and non-motor deficits (depression and cognitive impairments), enhanced antioxidant enzyme activities (p<0.01), and attenuated neurotransmitter alterations (p<0.01). It is suggested that quercetin supplementation improves neurotransmitter levels by mitigating oxidative stress via increasing antioxidant enzyme activity and hence improves motor activity, cognitive functions, and reduces depressive behavior. The results of the present study showed that quercetin pre-supplementation produced more significant results as compared to post-supplementation. These findings show that quercetin can be a potential therapeutic agent to reduce the risk and progression of PD.


Asunto(s)
Antioxidantes/administración & dosificación , Disfunción Cognitiva/inducido químicamente , Disfunción Cognitiva/tratamiento farmacológico , Depresión/inducido químicamente , Depresión/tratamiento farmacológico , Actividad Motora/efectos de los fármacos , Fármacos Neuroprotectores/administración & dosificación , Enfermedad de Parkinson Secundaria/inducido químicamente , Enfermedad de Parkinson Secundaria/tratamiento farmacológico , Quercetina/administración & dosificación , Rotenona/toxicidad , Animales , Conducta Animal/efectos de los fármacos , Cognición/efectos de los fármacos , Disfunción Cognitiva/metabolismo , Depresión/metabolismo , Modelos Animales de Enfermedad , Masculino , Neurotransmisores/metabolismo , Estrés Oxidativo/efectos de los fármacos , Enfermedad de Parkinson Secundaria/metabolismo , Ratas , Ratas Wistar , Rotenona/administración & dosificación , Transducción de Señal/efectos de los fármacos , Resultado del Tratamiento
16.
Life Sci ; 256: 118014, 2020 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-32593712

RESUMEN

The age and strength of fear memory are two potential parameters that can be influenced by the impairing effects of pharmacological agents on reconsolidation of fear memory. In reconsolidation, stored information is rendered labile again after being reactivated. Pharmacological manipulations at this stage result in an inability to retrieve the fear memories, suggesting that they are erased or persistently inhibited. This fear memory impairment phenomenon can be valuable to treat post-traumatic stress disorders (PTSD). Previously ß-adrenergic antagonist propranolol has been repeatedly reported to impair fear memory in the treatment of PTSD. Atropine has also shown to disrupt memory formation. The present study was therefore designed to compare the effects of atropine and propranolol on reconsolidation of older fear memory in rat model of PTSD using Pavlovian fear conditioning apparatus. For this purpose 18 rats were taken and divided into control, atropine and propranolol groups and subjected to Pavlovian fear conditioning trials in order to develop animal model of PTSD. To evaluate the reconsolidation impairment of fear memory by atropine and propranolol, short term and long term memory was tested after reactivation of fear memory in rats. The present findings demonstrate that atropine significantly decreases fear expression. These results suggest that atropine significantly reduces the strength of fear memories and may be effective in the treatment of psychiatric disorders especially in PTSD.


Asunto(s)
Atropina/farmacología , Miedo/efectos de los fármacos , Propranolol/farmacología , Trastornos por Estrés Postraumático/tratamiento farmacológico , Antagonistas Adrenérgicos beta/farmacología , Animales , Condicionamiento Clásico/efectos de los fármacos , Modelos Animales de Enfermedad , Masculino , Memoria/efectos de los fármacos , Antagonistas Muscarínicos/farmacología , Ratas , Ratas Wistar , Receptores Muscarínicos/efectos de los fármacos , Receptores Muscarínicos/metabolismo , Trastornos por Estrés Postraumático/fisiopatología
17.
PLoS One ; 15(1): e0227631, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-31945778

RESUMEN

Currently prescribed medications for the treatment of Alzheimer's disease (AD) that are based on acetylcholinesterase inhibition only offer symptomatic relief but do not provide protection against neurodegeneration. There appear to be an intense need for the development of therapeutic strategies that not only improve brain functions but also prevent neurodegeneration. The oxidative stress is one of the main causative factors of AD. Various antioxidants are being investigated to prevent neurodegeneration in AD. The objective of this study was to investigate the neuroprotective effects of naringenin (NAR) against AlCl3+D-gal induced AD-like symptoms in an animal model. Rats were orally pre-treated with NAR (50 mg/kg) for two weeks and then exposed to AlCl3+D-gal (150 mg/kg + 300 mg/kg) intraperitoneally for one week to develop AD-like symptoms. The standard drug, donepezil (DPZ) was used as a stimulator of cholinergic activity. Our results showed that NAR pre-treatment significantly protected AD-like behavioral disturbances in rats. In DPZ group, rats showed improved cognitive and cholinergic functions but the neuropsychiatric functions were not completely improved and showed marked histopathological alterations. However, NAR not only prevented AlCl3+D-gal induced AD-like symptoms but also significantly prevented neuropsychiatric dysfunctions in rats. Results of present study suggest that NAR may play a role in enhancing neuroprotective and cognition functions and it can potentially be considered as a neuroprotective compound for therapeutic management of AD in the future.


Asunto(s)
Acetilcolinesterasa/metabolismo , Enfermedad de Alzheimer/tratamiento farmacológico , Flavanonas/farmacología , Fármacos Neuroprotectores/farmacología , Síndromes de Neurotoxicidad/prevención & control , Acetilcolinesterasa/genética , Cloruro de Aluminio/toxicidad , Enfermedad de Alzheimer/metabolismo , Enfermedad de Alzheimer/patología , Animales , Antioxidantes/farmacología , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Encéfalo/patología , Cognición/efectos de los fármacos , Modelos Animales de Enfermedad , Función Ejecutiva/efectos de los fármacos , Galactosa/toxicidad , Masculino , Síndromes de Neurotoxicidad/etiología , Estrés Oxidativo/efectos de los fármacos , Ratas Wistar
18.
Life Sci ; 217: 202-211, 2019 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-30528774

RESUMEN

AIMS: Due to rapid increase in industrialization in the last few years, use of aluminum (Al) and its alloys have been increased in different industrial fields. Ample evidence supports the neurotoxic effects of chronic aluminum chloride (AlCl3) administration in rats but acute Al toxicity has been less described so the present study was aimed to investigate the neurotoxic effects of acute AlCl3. MAIN METHODS: To investigate such effects 12 male albino Wistar rats were randomly divided into control and test rats. AlCl3 at a dose of 150 mg/kg was intraperitoneally injected to test rats for 7 days. Rats were subjected to behavioral assessments 24 h after last dose and after behavioral assessment rats were sacrificed to collect brain samples for further neurochemical, biochemical and histopathological examinations. KEY FINDINGS: In the present study acute administration of AlCl3 resulted in noticeable behavioral deficits. Cognitive deficits and neuropsychiatric disturbances were evident in AlCl3 injected rats. Test rats also exhibited marked antioxidant enzymes, cholinergic, serotonergic and dopaminergic dysfunctions and DNA fragmentation. Histopathological alterations were observed in hippocampus and cortex of rats injected with AlCl3. SIGNIFICANCE: The observed effects may be due to pro-oxidant nature of Al and its participation in free radical mediated cellular injury. Al by promoting oxidative stress, impairing antioxidant defense system and altering brain neurochemistry may act as a potent neurotoxic agent as evident from observed histopathological alterations in brain of test rats. This investigation may further confirm and shed some more light on deleterious effects of acute Al intoxication on brain.


Asunto(s)
Cloruro de Aluminio/toxicidad , Encéfalo/efectos de los fármacos , Encéfalo/patología , Daño del ADN/efectos de los fármacos , Transmisión Sináptica/efectos de los fármacos , Animales , Encéfalo/metabolismo , Encéfalo/fisiopatología , Cognición/efectos de los fármacos , Masculino , Estrés Oxidativo/efectos de los fármacos , Ratas Wistar
19.
Life Sci ; 194: 213-223, 2018 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-29287782

RESUMEN

AIMS: Free radical mediated neurotoxicity is a leading cause of neurodegenerative disorders. Neurodegeneration due to oxidative stress can produce cognitive dysfunctions. Flavonoids and curcuminoids are naturally occurring polyphenolic compounds that display a variety of therapeutic importance against oxidative stress. MAIN METHODS: This study was designed to assess potential role of polyphenolic compounds in neurocognitive functions and prevention against oxidative stress. For this purpose, young rats were orally treated with naringenin (NAR), curcumin (CUR) and quercetin (QUE) at a dose of 50mg/kg, 200mg/kg and 50mg/kg respectively for 16days. At 4th day of drug administration cognitive functions were monitored by Morris water maze (MWM) test. In MWM cognitive functions in terms of learning acquisition (1h after training), retention (24h after training), memory extinction (4days after training), and reconsolidation (8 and 12days after training) were monitored. Biochemical and neurochemical analysis were done in whole brain. KEY FINDINGS: Treatment of NAR, CUR and QUE significantly enhanced learning acquisition, memory retention and reconsolidation and prevented memory extinction. Treatment of NAR and QUE prevented the alteration of brain antioxidant defence system by enhancing antioxidant enzyme activities and increasing antioxidant compound concentration. Oxidative stress in terms of lipid peroxidation was significantly prevented in treated rats. Serotonergic and cholinergic improvement was also found in treated rats. SIGNIFICANCE: The present study therefore provides biological evidence supporting the usefulness of these polyphenolic compounds in daily life for improvement of cognitive abilities and hence may have a potential role in the management of dementia and related disorders.


Asunto(s)
Antioxidantes/farmacología , Cognición/efectos de los fármacos , Curcumina/farmacología , Flavanonas/farmacología , Memoria/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Quercetina/farmacología , Acetilcolina/metabolismo , Acetilcolinesterasa/metabolismo , Animales , Antioxidantes/administración & dosificación , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Colinérgicos/farmacología , Curcumina/administración & dosificación , Flavanonas/administración & dosificación , Masculino , Quercetina/administración & dosificación , Ratas , Ratas Wistar , Serotonina/metabolismo
20.
Brain Res Bull ; 120: 63-74, 2016 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-26548495

RESUMEN

Dietary nutrients may play a vital role in protecting the brain from age-related memory dysfunction and neurodegenerative diseases. Tree nuts including almonds have shown potential to combat age-associated brain dysfunction. These nuts are an important source of essential nutrients, such as tocopherol, folate, mono- and poly-unsaturated fatty acids, and polyphenols. These components have shown promise as possible dietary supplements to prevent or delay the onset of age-associated cognitive dysfunction. This study investigated possible protective potential of almond against scopolamine induced amnesia in rats. The present study also investigated a role of acetylcholine in almond induced memory enhancement. Rats in test group were orally administrated with almond suspension (400 mg/kg/day) for four weeks. Both control and almond-treated rats were then divided into saline and scopolamine injected groups. Rats in the scopolamine group were injected with scopolamine (0.5 mg/kg) five minutes before the start of each memory test. Memory was assessed by elevated plus maze (EPM), Morris water maze (MWM) and novel object recognition (NOR) task. Cholinergic function was determined in terms of hippocampal and frontal cortical acetylcholine content and acetylcholinesterase activity. Results of the present study suggest that almond administration for 28 days significantly improved memory retention. This memory enhancing effect of almond was also observed in scopolamine induced amnesia model. Present study also suggests a role of acetylcholine in the attenuation of scopolamine induced amnesia by almond.


Asunto(s)
Trastornos de la Memoria/dietoterapia , Prunus dulcis , Acetilcolina/metabolismo , Acetilcolinesterasa/metabolismo , Animales , Modelos Animales de Enfermedad , Lóbulo Frontal/metabolismo , Hipocampo/metabolismo , Aprendizaje por Laberinto , Trastornos de la Memoria/metabolismo , Distribución Aleatoria , Ratas Wistar , Reconocimiento en Psicología , Escopolamina , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA